GlassScriptPhysician profile
Katie Gruen
NPI 1568903458
$5,561.30
in general payments reported to CMS, 2019-2025
21 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $909 · 2023: $1,773 · 2024: $1,500 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,609.05 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $982.02 | 2021-2025 | |
| Medtronic, INC. | $706.73 | 2021-2024 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $691.85 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Collegium Pharmaceutical, INC. | $371.49 | 2023-2025 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $207.75 | 2025 | Prospera |
| Vertos Medical, INC. | $206.96 | 2021-2023 | Mild Device Kit |
| Relievant Medsystems, INC. | $178.79 | 2021-2023 | Intracept |
| Curonix LLC | $170.60 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.54 | 2023-2025 | Relistor |
| Novo Nordisk INC | $74.56 | 2023-2024 | Ozempic, Rybelsus |
| Globus Medical, INC. | $47.35 | 2025 | Senza |
| Biodelivery Sciences International, INC. | $38.33 | 2021 | |
| Amgen INC. | $28.42 | 2021-2024 | Evenity |
| Almatica Pharma LLC | $25.56 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $20.33 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.17 | 2023 | Iovera, Zilretta, Exparel |
| Lilly USA, LLC | $17.76 | 2023 | Reyvow, Emgality |
| Bioventus LLC | $16.08 | 2023 | Stimrouter Implantable Kit |
| Merck Sharp & Dohme LLC | $15.01 | 2024 | Capvaxive, Vaxelis, Gardasil |
| Kowa Pharmaceuticals America, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Gruen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.